Concourse Financial Group Securities, Inc. Travere Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$7.89 - $15.21 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$5.26 - $8.28 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$7.18 - $9.82 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$5.44 - $9.5 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$7.64 - $17.25 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$7.64 - $17.25 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$15.3 - $22.61 $0 - $0
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$18.47 - $26.14 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$22.91 - $28.63 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$20.94 - $30.01 $0 - $0
Q1 2022 May 09, 2022	BUY	$23.61 - $30.6 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$24.34 - $31.17 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$12.98 - $25.03 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $0 - $0
Q1 2021 May 13, 2021	BUY	$23.37 - $31.77 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$19.17 - $27.87 $0 - $0

Others Institutions Holding TVTX

# of Institutions

193

Shares Held

84.6M

Call Options Held

776K

Put Options Held

900K

Armistice Capital, LLC New York, NY

7.65M
Shares

$140 Million
1.78% of portfolio
Black Rock Inc. New York, NY

7.64M
Shares

$140 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.9M
Shares

$126 Million
0.0% of portfolio
Rock Springs Capital Management LP Baltimore, MD

4.68M
Shares

$85.5 Million
2.23% of portfolio
Woodline Partners LP San Francisco, CA

4.34M
Shares

$79.2 Million
0.55% of portfolio

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.17B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account